The Turkish NSCLC market
will grow at a rate of 7% per year between 2012 and 2017, and the number of
NSCLC incident cases will grow by nearly 30% between 2012 and 2022. Changing
medical practice, growing NSCLC population, and persistent use of branded
agents offer significant opportunity to multinational companies (MNCs) with
emerging therapies in this indication. In this report, we examine the trends
within Turkey’s NSCLC pharmaceutical market, which is characterized by the growing
use of targeted therapies, changes in reimbursement policy, the
introduction of several new agents, and the Turkish government’s stringent
Questions Answered in This Report:
Between 2012-2017, eight new therapies are expected to enter
Turkey’s NSCLC market. Will they be new entrants to the existing drug
classes or will they feature novel mechanisms of action? How widely will
these agents be used in Turkey, in which histological subtypes and lines of treatment?
What are Turkish oncologists’ perceptions of the emerging therapies?
Pricing of therapies and reimbursement policies in the
public sector are major factors influencing expenditure on NSCLC treatments in Turkey.
How does the pricing of branded and generic agents used in treatment of NSCLC
differ between Turkey and the major markets? Which groups of Turkish
patients are eligible for government-reimbursed treatment of NSCLC? Which
therapies are currently not readily available to the Turkish patients, and is
it likely that the patient shares of those agents will increase substantially
in the next several years?
The Turkish NSCLC market will grow at 7% annually between
2012 and 2017. What was the size of the Turkish NSCLC market in 2012? How
large will the market be in 2017? What factors will drive growth in this
market? What factors will constrain it?
The number of incident cases of NSCLC in Turkey will
increase by nearly 30% between 2012 and 2022. What was the number of
incident cases of NSCLC in Turkey in 2012? How many of them were male? How were
the cases distributed between histological subtypes and stages of disease? What
will be the main causes for incident population growth?
Primary research: 73 oncologists surveyed across Turkey.
Separate in-depth interviews with 8 Turkish oncologists.
Epidemiology: Total incident cases of NSCLC in Turkey
over a ten-year period (2012-2022) by age, stage, gender, and histology.
Current therapies and medical practice: Reporting use
of brands and generics for the NSCLC treatments available in Turkey.
Pricing and reimbursement: Prices of NSCLC therapies
in Turkey versus other major markets and analysis of the impact of government
reimbursement on treatment trends.
Market forecast features: Our analysis evaluates
rates of NSCLC progression and rates of drug treatment with NSCLC therapies,
across all stages of the disease. We include a detailed forecast of current and
emerging therapies within platinum agents, antitubulins, antimetabolites, other
cytotoxic agents, EGFR inhibitors, angiogenesis inhibitors, ALK inhibitors,
immunotherapies, and c-Met inhibitors from 2012 through 2017, using a
combination of historical trend analysis and an epidemiology-based, bottom-up